ArticleTranslational andrology and urology2025
Efficacy of presurgical therapy with tislelizumab and axitinib to downsize local lesions in locally advanced and metastatic renal cell carcinoma: a single-institution experience with long-term follow-up.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic therapy with or without surgery is recommended in advanced renal cell carcinoma (RCC). The potential benefits of tislelizumab and axitinib as presurgical therapy in advanced RCC remain unclear. This study aimed to preliminarily assess the efficacy of short-term presurgical tislelizumab and axitinib in downsizing local lesions and its long-term oncological outcome with or without nephrectomy in advanced RCC. Methods: Data were prospectively collected from patients with advanced RCC who received tislelizumab and axitinib and were scheduled for deferred nephrectomy. Efficacy was evaluated by the remission of all tumor lesions using computed tomography (CT), and oncological outcomes were also reported. Results: Between March 2021 and May 2022, 11 patients were recruited, 10 of whom presented with metastases. Biopsy results confirmed clear-cell RCC in eight patients, and RCC not otherwise specified in three patients. Following a median of three cycles of presurgical treatment, the overall response rate (ORR) and disease control rate (DCR) were 18.2% (2/11) and 100% (11/11), respectively. The median percentage change in the long-axis diameter was -24.0% (range, -8.2% to -39.7%) for all lesions and -12.2% (range, -7.1% to -39.7%) for local lesions. Open nephrectomy was successfully performed in eight patients with high anatomical complexity. After a median follow-up of 23 months (range, 14-34 months), six patients (6/11, 54.5%) experienced disease progression and died, including three patients without nephrectomy (3/3, 100%) and another three with nephrectomy (3/8, 37.5%). Progression-free survival (PFS) and overall survival (OS) were significantly longer in patients who underwent nephrectomy (P=0.002 and P=0.004). Conclusions: Short-term presurgical tislelizumab and axitinib can downsize local lesions and facilitate nephrectomy in advanced RCC with high anatomical complexity, potentially improving long-term oncological outcomes when followed by cytoreductive surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.